Back to search results

Observational Study on Growth Hormone and Type 2 Diabetes Risk

This study at the University of Missouri is looking at how beta-cells (cells in your pancreas that make insulin to control blood sugar) respond to growth hormone. Researchers want to understand if there's a difference in this response for people who have a family history of type 2 diabetes compared to those who don't. The study aims to learn more about how growth hormone affects beta-cells and factors that might increase the risk of developing type 2 diabetes. They will measure beta-cell function before and 7 days after giving rhGH (recombinant human growth hormone). They are looking for about 30 healthy adults who are 18 to 59 years old and have a body mass index between 30.0 and 45.0 kg/m2.

Study design
This is an observational study with about 30 participants. It compares people with a family history of type 2 diabetes to a control group without such a history.
What's involved
Participants will have their beta-cell function measured before and 7 days after receiving rhGH. The specific number of visits or other procedures is not detailed.
Compensation
Not stated in the trial record.
Follow-up
Beta-cell function is measured at 7 days after rhGH administration, indicating a short follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06571500

Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes

Recruiting
Not specifiedAges 18–59Observational
University of Missouri-Columbia
~30 participants
Updated 2026-05-11 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Beta-cell function
Measured over before and 7 days after rhGH administration

Conditions

Healthy
Obesity

Explore related trials

HealthyObesity

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Bettina Mittendorfer, PhD · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia

Who to contact

Amanda Heider
[email protected]
573-884-6852
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 to 59 years old
body mass index ≥30.0 kg/m2 and \<45.0 kg/m2
Family history of type 2 diabetes: first degree relative with type 2 diabetes
Control group: no family history of type 2 diabetes

Exclusion

Pregnant, planning to become pregnant during the study, or breastfeeding
Current diagnosis or history of type 1 or type 2 diabetes
Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
History of bariatric surgery
Known, uncontrolled hypothyroidism
History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
Current cancer or cancer that has been in remission less than 5 years
First degree relative with type 1 diabetes diagnosis
Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

What this trial measures

  • Beta-cell functionbefore and 7 days after rhGH administration

    Insulin secretion rate in relationship to plasma glucose